Figure 2

Photomicrographs showing the pathological changes occuring in HepG2 cancer cells after individuals treatments using 100 × magnification. The pathological changes were as follows: (A) untreated HepG2 cells (control) showing regular cells with hyperchromatic nuclei and nuclear pleomorphism; (B) Sorafenib treated cells showing nuclear fragmentation (yellow arrows), necrotic cells with mixed euochromatin and heterochromatin (green arrows), ruptured cell membrane (red arrow), peripheral condensation of chromatin (black arrow) and shrunken apoptotic cells (blue arrow); (C) Bevacizumab treated cells showing apoptotic features of shrunken cells, shrunken nuclei, shrunken apoptotic cells (red arrows) and peripheral condensation of chromatin (green arrows); (D) Panitumumab treated cells showing shrunken apoptotic (blue arrows) with peripheral condensation of chromatin (orange arrows) and apoptotic body (red arrow), and (E) Ramucirumab treated cells showing cellular and nuclear shrinkage (yellow arrow), irregularities of cellular and nuclear outlines (green arrows), peripheral condensation of chromatin (red arrow) and membrane blebbing (blue arrow).